The FDA has expedited review of two Jubilant HollisterStier (JHS) manufacturing sites to manufacture some imaging agents that had been made at the beleaguered Ben Venue plant in Bedford, OH. Meara Murphy, a spokeswoman for developer Lantheus Medical Imaging, tells Outsourcing-Pharm.com that manufacture of the products is moving to JHS facilities in Washington and Maryland. She said the company will continue to work with Ben Venue until the end of the year to ensure adequate supplies during the transition. The products were in short supply in 2012 because of problems at the Ben Venue plant. Ben Venue, the Boehringer Ingelheim contract manufacturing arm, recently signed a consent decree with the FDA that bars the plant from manufacturing some drugs until the agency is satisfied that problems at the plant have been rectified. But the FDA also is allowing it to continue to manufacture 100 drugs considered "essential for patient care" while keeping a close eye on drug quality. Story | More